More Videos
- Readers Get Short With Me--Over Amgen
- Biopharma Analyst Musical Chairs
- Abbott, Boston Scientific Stents & Stuff
- A "Short" Story On Amgen
- Merck Muscles In On Migraines
- Boston Scientific: Hurry To The Pre-4th of July Sale On Stents!?
- Credit Suisse Healthier 15: Investors Get Skinny On Fat Fighters
- FDA Delivers One-Two Punch To Merck & Lilly
- Lilly's Effient Empire
- Pfizer and the State of Statins
- The Week: Pickers Focus on Steel, Financials, Tech & International Stocks
- Bowyer: Back to Monarchy in Land Rights?
- Parking Cash in European Telecoms
- Bargain Stocks: Nokia, Spectra, Incitex Pivot
- Sticker Shock: Fast Money's Inflation Special
- Our Favorite Inflation Trades
- Warren Buffett's Annual Stock Gift to Gates Foundation Worth $1.8B This Year
- That '70's Trade
- The Villain Of Our Story
- Geopolitical Concerns Keep Oil Supported near $144
- South Korea Won Jumps on Intervention Warning
- Asian Markets Are Mixed, Shanghai Leads
- Will Smith Tops Box Office with 'Hancock'
- NBC Universal to Buy The Weather Channel
- Merrill Will Decide on BlackRock Stake Sale Soon
- For Stocks, Escaping Bear Hinges on Oil, GE
- Bush Backs Strong Dollar Policy
- Merrill May Be Close to Selling Bloomberg Stake: Report
 |
CNBC.com |
] and Schering-Plough [SGP
Loading...
()
] announced that the Food and Drug Administration won't approve their combo Claritin-Singulair combo pill for allergies.Analysts didn't have high hopes for the drug (especially after the agency recently revealed it's investigating a possible association between Singulair and suicidal behavior), so investors seem to be shrugging off the news.
In fact, MRK shares are rallying this morning ahead of an anticipated FDA decision sometime today on its cholesterol drug called Cordaptive. It's a combo of Niacin and a special ingredient to reduce the facial flushing side effects of Niacin. Analyst estimates for peak sales of Cordaptive range from a few hundred million bucks a year to billion-dollar blockbuster status.
Abbott Labs [ABT
Loading...
()
] makes a Niacin drug called Niaspan which could possibly take a hit if/when Cordaptive gets approved. Today is the date given as the PDUFA (Prescription Drug User Fee Act) or what, in plain English, I like to call the"action day" for an FDA Cordaptive decision in case you're wondering how people know when this kind of stuff is gonna happen.
Also late Friday, Bristol-Myers Squibb [BMY
Loading...
()
] and Medarex [MEDX
Loading...
()
] announced a regulatory delay for their skin cancer treatment. MEDX shares hit a new intra-day low earlier this morning. The FDA wants the companies to test and see if the drug helps people live longer rather than just extending the amount of time that goes by before the cancer worstens.
Meantime, after dueling data presentations at a scientific conference in Milan over the weekend, analysts are declaring Vertex Pharmaceuticals [VRTX
Loading...
()
] the winner versus Schering-Plough in the latest round of the Hepatitis C drug battle. Vertex is partnered with Johnson and Johnson [JNJ
Loading...
()
] on telaprevir. Wachovia's George Farmer calls SGP's data "underwhelming" and says VRTX's data "positions telaprevir as the (Hepatitis C drug) of choice between these two candidates." Leerink Swann's Howard Liang says Schering's drug is "in the game" but adds, "Advantage goes to telaprevir."
related content |
Hep C doesn't get much mainstream media play, but in medical and investment circles it is considered to be a big area of unmet need and a potential goldmine for drug companies that can develop better treatments. The drugs on the market today don't work on many patients and can make them feel like they have the flu. VRTX and SGP have the most mature pipeline products, but other companies are also in various earlier stages of developing Hep C drugs.
Wachovia and Leerink Swann make a market in VRTX and LS trades in SGP.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes